Supernus Q1 2025: Qelbree sales +44% to $64.7M; ONAPGO launched; total revenue +4% to $149.8M

SUPERNUS PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$0.21 revenue$149,824,000

First quarter 2025 total revenue $149.8M, up 4% YoY; operating loss $(10.3)M vs $(3.2)M in prior year.
Qelbree net sales $64.7M (+44% YoY); GOCOVRI net sales $30.7M (+16% YoY).
ONAPGO (apomorphine infusion) launched in U.S. in April 2025 for Parkinson's motor fluctuations.
Adjusted operating earnings (non-GAAP) increased 16% to $25.9M; full year 2025 guidance reaffirmed.
Qelbree prescriptions grew 22%; March 2025 monthly Rx hit all-time high of 75,277.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.